Oncology Repurposing Engine

Our proprietary data analytics tool, ORE™, synthesizes the plethora of scientific and real-world data on non-cancer generic drugs, and rapidly identifies the most promising therapies to be repurposed for cancer

 
3 step approach.png
 

Developing cancer treatments based on generics reduces time to market and creates affordable treatment options

 

Announcements

Laura Kleiman was interviewed on the New England Cable News CEO Corner. Watch it here: Part 1 and Part 2

We were voted the MassChallenge startup most likely to change the world and named one of the Top 20 startups! Read about it here

We are excited to partner with MIT, Harvard, and Wellesley business students through the MIT Entrepreneurship Lab

We launched collaborations with IBM Research’s Science for Social Good Initiative, Innoplexus, and Byron Wallace’s group at Northeastern University to build our Oncology Repurposing Engine™. Learn more here

Laura Kleiman recently presented at the FDA’s Oncology Center of Excellence Drug Repurposing for Oncology Rare Diseases Mini-Symposium, IBM Research, and the Annual Drug Repositioning and Repurposing Conference

Cures Within Reach and repurposing off-patent drugs were discussed in The Economist. Read the article here